In a new advice published today, the Commission’s Scientific Advice Mechanism recommends improvements to existing screening programmes for cervical cancer, breast cancer and colorectal cancer — by adopting new technologies, expanding the age range of screening, and optimising how frequently people are screened depending on age, sex and previous test results.
Furthermore, the experts found a strong scientific basis for introducing life-saving screening programmes in EU member states for both lung cancer and prostate cancer.
The field of cancer screening is rapidly evolving, and in 2022 the European Commission will make a proposal to update the Council Recommendation on cancer screening to ensure it reflects the latest available scientific evidence.
Leading cancer experts from across the world discussed the latest scientific progress in a series of three full-day scientific meetings held at the end of 2021, chaired jointly by Professors Rebecca Fitzgerald (University of Cambridge) and Harry de Koning (Erasmus MC Medical Centre, Rotterdam), under the auspices of FEAM.
The experts’ conclusions, supported by a review of the scientific literature conducted by Cardiff University, are detailed in the latest SAPEA Evidence Review Report. This evidence in turn informs the Scientific Opinion of the Group of Chief Scientific Advisors, also published today (2 March).
Explore our Report and the Scientific Opinion at sapea.info/cancer and learn more about what the evidence suggests for successful screening programmes across Europe.